Back to search results

Feasibility and Efficacy of EndeavorRx in Sickle Cell Disease

This study is looking at whether a digital game called EndeavorRx can help children with sickle cell disease (SCD) improve their attention. Children with SCD often have trouble with attention and thinking skills. EndeavorRx is an FDA-approved program played on a tablet that uses game-like activities to challenge and improve attention. This study wants to see how easy it is for patients and families to use EndeavorRx, how many complete the program, and if they are satisfied with it. To join, you must be 8-16 years old, have SCD, be on monthly blood transfusions, and have specific attention difficulties identified by a test. The study plans to enroll 20 participants.

Study design
This is an interventional study with a planned enrollment of 20 participants. The phase of the study is not specified.
What's involved
You would use EndeavorRx on a tablet for 25-30 minutes each day, 5 days per week, for 4 weeks. You would also complete assessments related to patient/family interest, program completion, and technical ease-of-use and satisfaction.
Compensation
Not stated in the trial record.
Follow-up
Feasibility will be assessed at approximately 10 months for patient/family interest, and at approximately 4 weeks from the start of the intervention for program completion rates and satisfaction.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05099874

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

Recruiting
NAAges 8–16InterventionalTreatment
Children's National Research Institute
~20 participants
Updated 2025-01-10 on ClinicalTrials.gov
What's tested:EndeavorRx

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
EndeavorRx feasibility assessed by patient/family interest
Measured over Approximately 10 months
+2 more outcomes measured

Conditions

Sickle Cell Disease
Attention Deficit
Cognitive Deficit in Attention

Explore related trials

Attention Deficit DisorderSickle Cell Disease

Where it's being run

1 sites across 1 states
District of Columbia1

Study leadership

  • Steven J Hardy, Ph.D. · PRINCIPAL_INVESTIGATOR · Children's National Research Institute

Who to contact

Steven J Hardy, Ph.D.
[email protected]
202-476-5000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

diagnosis of SCD
ages 8-16 years
maintained on monthly blood transfusions consistently for at least 3 months.
patients will be proceed to the intervention phase only if they have a T-score \> 75th percentile for Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) or a T-score \> 75th percentile for the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V).

Exclusion

estimated Intelligence Quotient \< 70
motor, visual, or auditory impairment that prevents computer use
known diagnosis of a mental health condition that precludes, or takes treatment precedence over, participation in cognitive training
history of photosensitive seizures
insufficient English fluency.

What this trial measures

  • EndeavorRx feasibility assessed by patient/family interestApproximately 10 months

    Feasibility will be determined by examining the proportion of eligible patients/families approached about the study who enroll.

  • EndeavorRx feasibility assessed by program completion ratesApproximately 4 weeks per participant

    Feasibility will be evaluated by examining the proportion of the sample that completes at least 60 EndeavorRx missions (50%).

  • EndeavorRx feasibility assessed by reports of technical ease-of-use and satisfactionApproximately 4 weeks from start of intervention

    Feasibility will be determined by examining parent and child reports of technical ease-of-use and satisfaction.